Genetic research advance yields new lupus treatment
The Food and Drug Administration approved the first new drug for lupus in more than 50 years, a major milestone in the effort to mine data from the human genome to discover and develop new medicines. The drug, called Benlysta, will be co-marketed by Human Genome Sciences Inc., a Rockville, MD, company that has been on a roller-coaster journey for nearly two decades to develop the medicine, and GlaxoSmithKline PLC, whose investment in the biotech company was one of the first big bets a major pharmaceutical company placed on genomic research. Analysts expect the drug to reach blockbuster status, with sales eventually topping $1 billion a year.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- FDA hopes hospitals will switch to newly regulated pharmacies
- The 5 Biggest Healthcare Finance Trouble Spots
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- Nonprofit Hospital Outlook 'Negative' in 2014
- The Most Polarizing Topics in Healthcare IT
- Are ACOs Really Different from HMOs?
- How CPOE Will Make Healthcare Smarter
- Why You Should Involve Patients in Nursing Handoffs
- Rise of the Chief Strategy Officer